Hepatocyte growth factor is associated with progression of atherosclerosis

The Multi-Ethnic Study of Atherosclerosis (MESA)

Elizabeth J. Bell, Paul A. Decker, Michael Y. Tsai, James S. Pankow, Naomi Q. Hanson, Christina L. Wassel, Nicholas B. Larson, Kevin P. Cohoon, Matthew J. Budoff, Joseph F. Polak, James H. Stein, Suzette J. Bielinski

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. Methods: Participants aged 45–84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6–4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01–1.08, p = 0.005). Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalAtherosclerosis
Volume272
DOIs
StatePublished - May 1 2018

Fingerprint

Hepatocyte Growth Factor
Atherosclerosis
Coronary Vessels
Calcium
Confounding Factors (Epidemiology)
Coronary Disease
Coronary Artery Disease
Cohort Studies
Cardiovascular Diseases
Biomarkers
Stroke
Prospective Studies

Keywords

  • Atherosclerosis
  • Cardiovascular risk factors
  • Carotid plaque
  • Coronary artery calcium
  • Hepatocyte growth factor

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Cite this

Hepatocyte growth factor is associated with progression of atherosclerosis : The Multi-Ethnic Study of Atherosclerosis (MESA). / Bell, Elizabeth J.; Decker, Paul A.; Tsai, Michael Y.; Pankow, James S.; Hanson, Naomi Q.; Wassel, Christina L.; Larson, Nicholas B.; Cohoon, Kevin P.; Budoff, Matthew J.; Polak, Joseph F.; Stein, James H.; Bielinski, Suzette J.

In: Atherosclerosis, Vol. 272, 01.05.2018, p. 162-167.

Research output: Contribution to journalArticle

Bell, EJ, Decker, PA, Tsai, MY, Pankow, JS, Hanson, NQ, Wassel, CL, Larson, NB, Cohoon, KP, Budoff, MJ, Polak, JF, Stein, JH & Bielinski, SJ 2018, 'Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)', Atherosclerosis, vol. 272, pp. 162-167. https://doi.org/10.1016/j.atherosclerosis.2018.03.040
Bell, Elizabeth J. ; Decker, Paul A. ; Tsai, Michael Y. ; Pankow, James S. ; Hanson, Naomi Q. ; Wassel, Christina L. ; Larson, Nicholas B. ; Cohoon, Kevin P. ; Budoff, Matthew J. ; Polak, Joseph F. ; Stein, James H. ; Bielinski, Suzette J. / Hepatocyte growth factor is associated with progression of atherosclerosis : The Multi-Ethnic Study of Atherosclerosis (MESA). In: Atherosclerosis. 2018 ; Vol. 272. pp. 162-167.
@article{04e8eda9041a47d883460339f56fbae8,
title = "Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)",
abstract = "Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. Methods: Participants aged 45–84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95{\%} CI: 1.6–4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4{\%} higher risk of new or additional carotid plaque (95{\%} CI: 1.01–1.08, p = 0.005). Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.",
keywords = "Atherosclerosis, Cardiovascular risk factors, Carotid plaque, Coronary artery calcium, Hepatocyte growth factor",
author = "Bell, {Elizabeth J.} and Decker, {Paul A.} and Tsai, {Michael Y.} and Pankow, {James S.} and Hanson, {Naomi Q.} and Wassel, {Christina L.} and Larson, {Nicholas B.} and Cohoon, {Kevin P.} and Budoff, {Matthew J.} and Polak, {Joseph F.} and Stein, {James H.} and Bielinski, {Suzette J.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.atherosclerosis.2018.03.040",
language = "English (US)",
volume = "272",
pages = "162--167",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Hepatocyte growth factor is associated with progression of atherosclerosis

T2 - The Multi-Ethnic Study of Atherosclerosis (MESA)

AU - Bell, Elizabeth J.

AU - Decker, Paul A.

AU - Tsai, Michael Y.

AU - Pankow, James S.

AU - Hanson, Naomi Q.

AU - Wassel, Christina L.

AU - Larson, Nicholas B.

AU - Cohoon, Kevin P.

AU - Budoff, Matthew J.

AU - Polak, Joseph F.

AU - Stein, James H.

AU - Bielinski, Suzette J.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. Methods: Participants aged 45–84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6–4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01–1.08, p = 0.005). Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.

AB - Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. Methods: Participants aged 45–84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6–4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01–1.08, p = 0.005). Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.

KW - Atherosclerosis

KW - Cardiovascular risk factors

KW - Carotid plaque

KW - Coronary artery calcium

KW - Hepatocyte growth factor

UR - http://www.scopus.com/inward/record.url?scp=85044574064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044574064&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2018.03.040

DO - 10.1016/j.atherosclerosis.2018.03.040

M3 - Article

VL - 272

SP - 162

EP - 167

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -